Biotech entity
pharma accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder. 17 pharmaceutical companies is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. Source depth averages 5.8 original sources per story, versus 4.4 across the same-window beat baseline.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder. 17 pharmaceutical companies is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. Source depth averages 5.8 original sources per story, versus 4.4 across the same-window beat baseline. Across a 123-day span, the pace is roughly 0.2 stories per week. Their average consequence score of 6.5 runs above the beat's 6.4 for that window. Food and Drug Administration appears in 4 tracked Biotech stories published from March 16, 2026 through July 16, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 268 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Food and Drug Administration. Shared-story counts are live from our verified record — not editorial picks.
Media Backlash
Health experts and advocacy groups label the bill's scientific claims regarding water pollution as unverified.
Bill Introduction
Rep. Mary Miller introduces the Clean Water For All Life Act in the House.
Press Conference
Miller and Kristan Hawkins (Students for Life) present the bill as an environmental protection measure.
Market Impact
Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty.
Refusal to File
Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application.
Grants Rescinded
The White House rescinds hundreds of millions in mRNA research grants as political rhetoric shifts.
Workaround Supported
FDA officials appear to support Moderna's plan to use data from a smaller trial as a workaround for control group concerns.
Collaboration Begins
Moderna starts working with the FDA on the design for its mRNA flu vaccine trials.
TrumpRx, the Trump administration's drug discount website, has secured voluntary pricing deals on only 92 brand-name drugs—less than 12% of the 800-plus products from 17 major pharmaceutical companies. High-cost therapies for inflammatory diseases, HIV, and cancer are largely excluded, raising doubts about industry's willingness to compromise on pricing without legislation.
HHS Secretary Kennedy warns that Chinese companies accounted for nearly half of global pharmaceutical licensing deals in 2025, prompting FDA actions to streamline early-stage trials and potentially reduce drug development times by 6 to 12 months. The shift could reshape US biotech competitiveness and investment returns.
House Republicans have introduced the Clean Water For All Life Act, a bill that seeks to restrict abortion pill access by framing fetal remains as environmental pollutants. The legislation would mandate 'catch kits' for patients, ban telehealth prescriptions, and impose severe criminal penalties including five-year prison sentences.
Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight.
Food and Drug Administration is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
